Sequential and Adaptive Designs

A fixed design commits to a single sample size and one analysis at the end. Sequential and adaptive designs allow looks at the data during the study and let you stop early (for benefit, harm, or futility) or modify the design — saving participants, time, and money. The catch: every interim look at the data is another chance to cross the significance threshold by luck, so the error rate must be controlled explicitly. Peeking at accumulating data and stopping the first time p < 0.05 can inflate the Type I error rate; the amount depends on the number and timing of looks, test, and correlation. This is the core problem these methods solve.

Why naive peeking fails

If you test at α = 0.05 at each of K interim analyses and stop at the first significant result, the overall false-positive rate generally exceeds 0.05. There is no universal inflation value for K looks. Calibrate the joint procedure (e.g. alpha spending with its required assumptions) so the cumulative error is controlled, then verify it under realistic null scenarios.

Group-sequential designs

Pre-plan a fixed number of interim analyses (e.g. at information fractions 25%, 50%, 75%, 100%) and use adjusted, more stringent boundaries at each look so the overall α is preserved. Common boundary families:

• Pocock: constant (equally stringent) nominal significance level at every look. Easier to stop early, but pays a larger penalty at the final analysis.
• O'Brien–Fleming: very stringent early (hard to stop in the first looks), relaxing toward the planned final α. Most popular in confirmatory trials because the final boundary is close to the unadjusted 0.05 and early stopping is reserved for dramatic effects.
• Alpha-spending functions (Lan–DeMets): generalize the above by defining how much α is "spent" as a function of information accrued, so the number and timing of looks can vary under a pre-specified, valid monitoring plan. Information fractions represent statistical information, not automatically enrolled-patient fractions. Do not choose extra looks because an unblinded effect is nearly significant; spending alone does not license such outcome-dependent monitoring. See the FDA adaptive-design guidance.

You can stop for:

• Efficacy — the effect crosses the upper boundary.
• Futility — the effect is so small that continuing is unlikely to ever reach significance (a non-binding or binding lower boundary / conditional power threshold).
• Harm — safety boundary crossed.

Group-sequential designs require a modestly larger maximum sample size than a fixed design (to pay for the looks), but the expected sample size is usually smaller under scenarios where trials often stop early; report it under both null and plausible alternatives.

Tooling

Use purpose-built boundary calculations; the bundled Python helpers generate allocation/DOE layouts, not interim boundaries. Official current options are:

• R [gsDesign::gsDesign](https://keaven.github.io/gsDesign/reference/gsDesign.html): k includes the final analysis, timing specifies information fractions, and test.type distinguishes one-sided, symmetric two-sided, and binding/nonbinding futility designs. Do not assume the default alpha=0.025 is a two-sided 0.05 test.
• R [rpact::getDesignGroupSequential](https://docs.rpact.org/reference/getDesignGroupSequential.html): configure kMax, informationRates, sided, alpha, typeOfDesign, and futility explicitly. These are documentation-verified pointers; this skill does not ship or runtime-test an R boundary calculation.
• For custom rules, simulate the whole sequential procedure (generate data, apply the boundaries look by look, repeat) to confirm the realized Type I error and to estimate expected sample size and power. This mirrors the simulation approach in the statistical-power skill and is the most flexible route.

Adaptive designs

Broader than group-sequential: the design itself can change at an interim based on accumulating data, within a pre-specified plan that still controls error. Main types:

• Sample-size re-estimation: recompute the required n at an interim using the observed nuisance parameter (e.g. the variance or control-arm rate), without unblinding the treatment effect. Protects against a misjudged variance at planning.
• Adaptive randomization: shift allocation probabilities toward the better- performing arm as data accrue (response-adaptive), or to improve covariate balance.
• Drop-the-loser / arm selection: start with several arms or doses and drop inferior ones at interims (seamless phase II/III).
• Adaptive enrichment: narrow enrollment to a subgroup that appears to benefit.

Adaptive designs are powerful but easy to get wrong: any adaptation that uses the unblinded treatment effect can inflate Type I error and bias the final effect estimate unless the method explicitly corrects for it. Two non-negotiables:

1. Pre-specify the adaptation rule and the error-control method before the study.
2. Validate by simulation that the entire procedure preserves the Type I error rate and yields acceptable power, estimator bias, confidence-interval coverage, and expected/maximum sample sizes; report Monte Carlo uncertainty.

When to use them

• Confirmatory trials, expensive or risky enrollment — group-sequential with O'Brien–Fleming boundaries to allow ethical early stopping.
• Uncertain nuisance parameters at planning — blinded sample-size re-estimation.
• Many candidate doses/arms — adaptive arm selection / seamless designs.
• Pure exploration / fixed cheap data — usually not worth the overhead; a fixed design is simpler and the analysis is unambiguous.

Practical checklist

• Decide the number and timing of interim analyses (or the spending function).
• Choose a boundary family matched to how eager you are to stop early.
• Specify futility rules if you want to stop for lack of effect.
• Inflate the maximum sample size to cover the looks; report the expected sample size too.
• Pre-register the full sequential/adaptive plan, including the stopping rules.
• Have an independent data monitoring committee look at unblinded interims in human trials, not the study team.
• Simulate the design end to end to confirm error control before running it.